Skip to main content
Ad (425x293)

Boots launches medical cannabis prescribing service for UK patients

Boots has become the first major UK high street pharmacy to offer medical cannabis prescribing through its new SureLeaf online service. The service targets patients aged 25 and older with conditions such as chronic pain, anxiety and insomnia

By The UK Pulse Editorial Team·Source: The Guardian··4 min read·How we work
Boots Sureleaf products Cannabis Flower and Cannabis Oil

Boots has announced it will begin prescribing medical cannabis through an online service, marking the first time a major UK high street pharmacy has offered this treatment. According to The Guardian, the SureLeaf service will be available to patients aged 25 and older with eligible conditions including chronic pain, anxiety and insomnia.

The pharmacy chain is launching the service alongside a collaborative research programme with the University of Nottingham designed to examine patient outcomes, prescribing practices and experience in treating chronic pain. This development comes as private cannabis prescribing has expanded significantly across the UK, with nearly two million unlicensed cannabis items prescribed privately in England over the 12 months reported in October 2026, prompting experts to warn about potential patient risks.

People walking past Boots chemist on Oxford Street
A Boots branch on Oxford Street in London. Photograph: Mike Kemp/In Pictures/

How will the prescribing process work?

Patients will begin by completing an online assessment to determine their suitability for treatment. A clinical team will then review their case before inviting them to a video consultation with a consultant. Boots emphasised that any prescription would undergo independent review by a multidisciplinary clinical team that includes a second, independent consultant before treatment begins. The pharmacy also stated that patients must first have attempted conventional treatments without success before being considered for medical cannabis, and that all patients would receive regular reviews throughout their treatment.

What are the clinical safeguards?

Dr David Gwynne, the medical director of Boots' online service, stressed the importance of careful prescribing decisions.

Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.
He explained that
SureLeaf has, therefore, been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.

Ad (425x293)

Why is Boots offering this service?

Jamie Kerruish, Boots' chief healthcare officer, highlighted the significant burden that ongoing pain places on patients' lives.

Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.
He added that
Ultimately, it's about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.

What is the current legal status of medical cannabis in the UK?

UK law changed on 1 November 2018 to allow doctors on the General Medical Council's specialist register to prescribe cannabis-based products for medicinal use when clinically appropriate, though NHS prescribing remains very limited. NHS guidance generally limits consideration to rare, severe epilepsy, chemotherapy-related nausea or vomiting, and multiple-sclerosis muscle stiffness or spasms. The 2018 change followed campaigns by families of children with treatment-resistant epilepsy, particularly the case of a young boy from Northern Ireland with severe epilepsy whose mother's advocacy led to cannabis oil access.

Because NHS prescribing options remain restricted, private clinics have become the main route through which patients access cannabis-based medicines for various conditions beyond those covered by the NHS, including psychiatric disorders and neurological conditions.

What does research say about medical cannabis effectiveness?

Scientific evidence on cannabis for medical use remains mixed. Researchers from universities in Sydney, Brisbane and Melbourne in Australia, and Bath in England, found "very little evidence" that cannabis was effective in treating anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder or opioid use disorder. However, they identified some evidence that medical cannabis products could reduce dependence on cannabis, relieve the symptoms of Tourette syndrome and help insomniacs sleep better.

Key Facts

  • Boots' SureLeaf service is the first medical cannabis prescribing offering from a major UK high street pharmacy chain
  • Patients must be aged 25 or older and have tried conventional treatments without success before being considered
  • All prescriptions require independent review by a multidisciplinary clinical team including a second consultant
  • The service is being developed alongside research with the University of Nottingham to examine patient outcomes and prescribing practices
  • Private cannabis prescribing has expanded significantly, with nearly two million unlicensed items prescribed in England in the 12 months to October 2026
Ad (425x293)

Related News